BBS9

Across TCGA pan-cancer cohorts, BBS9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BBS9 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BBS9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BBS9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where BBS9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.543	0.876	.014	25	view →
LUAD	OS	Quartile	All	0.442	0.912	.003	12	view →
LSCC	DFS	Median	II,III,IV	0.828	1.000	.003	12	view →
UCEC	OS	Quartile	III,IV	0.329	1.000	.027	8	view →
CCRCC	DFS	Tertile	All	0.913	0.654	.024	7	view →
PDAC	DFS	Median	All	0.730	0.849	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BBS9–HNSC (OS)

Open the HNSC breakdown →